US Patent

US12084449 — Imidazotriazines and imidazopyrimidines as kinase inhibitors

Method of Use · Assigned to Incyte Corp · Expires 2027-11-19 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines as kinase inhibitors for treating cancer and other diseases.

USPTO Abstract

The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2813`	—	capmatinib-hydrochloride
`U-2813`	—	capmatinib-hydrochloride

Patent Metadata

Patent number: US12084449
Jurisdiction: US
Classification: Method of Use
Expires: 2027-11-19
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.